← Leaderboards
Gregory William Henkel
Arisan Therapeutics, Inc.
$14,774,797
Attributed
$16,674,797
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2011–25$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,674,797 · 7
By mechanism
R44$7,997,148 · 2
R01$5,459,651 · 1
SB1$2,000,000 · 1
R43$917,998 · 2
R41$300,000 · 1
Top collaborators
- Daniele Gerion2 shared
- Michael Bruno Plewe1 shared
- Ahmet Ali Yanik1 shared
Most similar at Arisan Therapeutics, Inc.
Same institution · by research overlap
- Ken J McCormack$1,995,261
- Michael Bruno Plewe$1,050,000
- Daniele Gerion$1,000,000
- Greg Henkel$3,692,037
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionPharmaceutical PreparationsDoseExhibitsGeographyPathogenCellsViral Hemorrhagic FeversMorbidity - Disease RateFamilyMortalityInfected Vector RodentExcretory FunctionTransmission ProcessOld World ArenavirusesTransplantationAfricaProphylacticEngineeringArenavirusSurvivorsViralIn VitroWeapons
Grant awards (18)
Initiation of ARN-75039 API and Drug Product NDA Registration Path and Manufacturing of Phase 3 final Drug Product$1,000,000
SB1 · FY2025 · AI · contact PI
IND-Enabling Studies for Arenavirus Preclinical Candidate$915,066
R01 · FY2025 · AI · contact PI
IND-Enabling Studies for Arenavirus Preclinical Candidate$1,065,105
R01 · FY2024 · AI · contact PI
Initiation of ARN-75039 API and Drug Product NDA Registration Path and Manufacturing of Phase 3 final Drug Product$1,000,000
SB1 · FY2024 · AI · contact PI
IND-Enabling Studies for Arenavirus Preclinical Candidate$1,085,888
R01 · FY2023 · AI · contact PI
IND-Enabling Studies for Arenavirus Preclinical Candidate$1,085,584
R01 · FY2022 · AI · contact PI
Pre-IND Development of an Arenavirus Antiviral$997,332
R44 · FY2022 · AI · contact PI
IND-Enabling Studies for Arenavirus Preclinical Candidate$1,308,008
R01 · FY2021 · AI · contact PI
Pre-IND Development of an Arenavirus Antiviral$999,816
R44 · FY2021 · AI · contact PI
Pre-IND Development of an Arenavirus Antiviral$1,000,000
R44 · FY2020 · AI · contact PI
Development of a Highly Sensitive Quantitative Rapid Digital LSPR Diagnostic for Acute Dengue and Zika Virus Infection$1,000,000
R44 · FY2020 · AI · contact PI
Development of a Highly Sensitive Quantitative Rapid Digital LSPR Diagnostic for Acute Dengue and Zika Virus Infection$1,000,000
R44 · FY2019 · AI · contact PI
Arenavirus Antiviral Lead Optimization$1,500,000
R44 · FY2017 · AI · contact PI
Arenavirus Antiviral Lead Optimization$1,500,000
R44 · FY2016 · AI · contact PI
Ultrasensitive Point-of-Care Diagnostics of Viral Biomarkers and Infectious Diseases$300,000
R41 · FY2016 · AI · contact PI
Identification of novel broad-spectrum Dengue antivirals$449,400
R43 · FY2014 · AI · contact PI
Identification of novel influenza antivirals$233,415
R43 · FY2012 · AI · contact PI
Identification of novel influenza antivirals$235,183
R43 · FY2011 · AI · contact PI